A recombinant MVMp of the fibrotropic strain of minute virus of mice (MVMp) expressing the chloramphenicol acetyltransferase reporter gene was used to infect a series of biologically relevant cultured cells, normal or tumor-derived, including normal melanocytes versus melanoma cells, normal mammary epithelial cells versus breast adenocarcinoma cells, and normal neurons or astrocytes versus glioma cells. As a reference cell system we used normal human fibroblasts versus the SV40-transformed fibroblast cell line NB324K. After infection, we observed good expression of the reporter gene in the different tumor cell types, but only poor expression if any in the corresponding normal cells. We also constructed a recombinant MVMp expressing the green fluorescent protein reporter gene and assessed by flow cytometry the efficiency of gene transduction into the different target cells. At a multiplicity of infection of 30, we observed
A recombinant MVMp of the fibrotropic strain of minute virus of mice (MVMp) expressing the chloramphenicol acetyltransferase reporter gene was used to infect a series of biologically relevant cultured cells, normal or tumor-derived, including normal melanocytes versus melanoma cells, normal mammary epithelial cells versus breast adenocarcinoma cells, and normal neurons or astrocytes versus glioma cells. As a reference cell system we used normal human fibroblasts versus the SV40-transformed fibroblast cell line NB324K. After infection, we observed good expression of the reporter gene in the different tumor cell types, but only poor expression if any in the corresponding normal cells. We also constructed a recombinant MVMp expressing the green fluorescent protein reporter gene and assessed by flow cytometry the efficiency of gene transduction into the different target cells. At a multiplicity of infection of 30, we observed Keywords: MVMp-based vectors; gene expression targeting; oncotropism; cytotoxic gene therapy; HSV-1 thymidine kinase
Although several viral vectors hold promise for in vivo gene therapy of cancer and although some are being tested clinically, 1 the lack of selectivity of these vectors may constitute a limitation, allowing nonspecific transduction of therapeutic genes into non-target healthy tissues. This drawback may be especially critical when cytotoxic effector genes are delivered in vivo. 2, 3 In order to avoid toxicity to normal cells, various targeting strategies are under study. 4 With various types of vector, specific targeting has been achieved by targetspecific delivery, 5, 6 by targeting cells with a particular replication status, 7 or thanks to differential transcriptional regulation of either transgene expression 4, 8 or viral replication and associated cytotoxicity. 9 Rather than restricting gene transduction to a specific tissue or cell type, we are investigating the possibility of targeting therapeutic genes into dividing neoplastic cells regardless of their tissue origin. Our approach exploits the inherent oncotropic properties of several low-pathogenic autonomous rodent parvoviruses, such as the fibrotropic strain of minute virus of mice (MVMp). 10 These small DNA viruses replicating in the nucleus 11, 12 display oncosuppressive activity in vivo and oncopreferential cell killing in vitro. The molecular basis of parvoviral oncotropism has not been fully elucidated, [13] [14] [15] [16] but current data indicate that the cellular changes associated with neoplastic transformation generally enhance cell susceptibility to lytic parvoviral infection. This enhanced susceptibility of transformed cells to killing by parvoviruses appears to coincide with a greater ability to sustain several steps of the parvoviral life cycle, particularly viral DNA replication and transcription. This selectivity may be due, at least in part, to differential regulation of expression from the early parvoviral promoter P4 15, 16 ( Figure 1 ). Activation of P4 leads to expression of the nonstructural (NS) genes, whose products are multifunctional proteins playing a key role in regulation of the parvoviral life cycle. They are notably required for viral DNA replication 17 and trans-activation of the second viral promoter, P38, which directs the expression of capsid genes. 18, 19 The NS proteins, moreover, exert cytotoxic activity in transformed cells. 20, 21 These various observations led to the idea that one might achieve tumorselective expression of a foreign gene by means of a parvoviral vector obtained by replacing the capsid protein genes with the foreign gene. 10 Vectors based on MVMp were constructed, expressing 46 The resulting recombinant virus stocks were purified and concentrated as described. 46 The rMVMp and RCPV titers of the different virus stocks were determined by replication center assay (RCA) on NB324K cells. 23 The rMVMp titers, whatever the recombinant, were always at least 5 × 10 8 
IU/ml. RCPV contamination of the recombinant virus stocks was approximately 0.05% for MVM/P38-GFP and less than 0.5% for both MVM/P38-CAT and MVM/P38-TK.
various foreign cDNAs/genes under the control of P38, notably human interleukin-2 and murine interleukin-4 cDNAs and the CAT reporter gene. 22, 23 Recombinants of MVMp (rMVMp) were produced by transient cotransfection of permissive cells with a vector plasmid containing the rMVMp genome and a complementary helper plasmid carrying the viral capsid genes. These MVMp-based vectors were shown in vitro to promote transgene expression in a variety of murine and human cells, this expression being transformation-dependent. 22, 23 The selective gene transfer potential of MVMp-based vectors has so far always been assessed at the level of the whole cell population (eg by CAT ELISA or CAT assay). The efficacy of cancer gene therapy depends primarily on the percentage of cells expressing the transgene in the infected cell population. One aim of the present work was to assess this important parameter in vitro, into a series of biologically relevant neoplastic versus normal, finite-life cells from different tissues, including normal Gene Therapy human fibroblasts (NHF) versus the SV40-transformed human fibroblastic cell line NB324K (serving as a reference cell system in this study), normal human melanocytes derived from a foreskin (NHM) or from a congenital nevus (NCG) versus two human melanoma cell lines (RPMI-7951, IGR3), normal human mammary epithelial cells (NHMEC) versus two human mammary adenocarcinoma cell lines (MCF-7, MDA-MB-231), and normal rat neurons (NRN) and astrocytes (NRA) versus the rat glioma cell line C6. Our second aim was to evaluate the possibility of exploiting the oncotropism of MVMp to achieve selective delivery of toxic effector genes into tumor cells. This was done by infecting the above-mentioned normal and tumor cells in vitro with an rMVMp carrying the HSV-TK suicide gene, then treating the infected cells with GCV.
We first checked for the presence of receptors for MVMp at the surface of the different normal and tumor cells used in this study (Table 1) . To this end, we pre- P-labeled MVMp (5 × 10 4 c.p.m. per dish) for 1 h at 37°C. The cells were then washed three times with PBS, harvested by trypsinization, and their radioactivity measured in a scintillation counter. The counts remaining after washing (bound radioactive label) were expressed as percentages of the total number of counts added per dish. Cells: all normal, finite-life cells were derived from a primary culture of the corresponding tissue; the NB324K 42 and IGR3 cell lines were provided by J Rommelaere (DKFZ, Heidelberg, Germany) and C Aubert (INSERM, Marseille, France); the RPMI-7951, MCF-7, MDA-MB-231 and C6 cell lines were provided by the American Type Culture Collection (ATCC, Rockville, MD, USA); NCG were grown as described; 43 NRN and NRA were obtained and cultured as described; 31 NHM and NHMEC were obtained from Promocell (Heidelberg, Germany) and Clonetics Corporation (Walkersville, MD, USA), respectively. a Positive control: highly permissive cell line used to produce MVMp. b Negative control: cells were incubated before infection with 0.1 U/ml neuraminidase (Boehringer, Mannheim, Germany) for 20 h to prevent virus binding to neuraminidase-sensitive, MVMp-specific cellular receptors. 24 pared a stock of 32 P-labeled wild-type (wt) MVMp particles and measured the uptake of radiolabeled particles by the different cell types. The specificity of the assay was tested by infecting permissive cells pre-treated with neuraminidase which, without inhibiting cell growth, inhibits subsequent MVMp infection by inactivating the specific cell surface receptors for MVMp particles. 24 In this experiment the amount of labeled MVMp particles incorporated into the different cell types varied from 24 to 64% of the initial infectious load (values for NRN and NHMEC, respectively) and there was no significant difference in virus uptake between normal and transformed cells. Thus, our binding data show that the selectivity of rMVMp is not due to the absence of cell surface receptors for MVMp on normal cells. It is most likely due to differential completion of several further, intracellular steps of the parvoviral life cycle, notably initiation of the synthesis of P4-driven viral transcripts, as previously demonstrated in normal versus EJ-ras-transformed rat fibroblasts. 25 We next examined the oncoselectivity of rMVMpmediated gene transduction by infecting the various cell models with a recombinant virus expressing the CAT reporter gene under control of the P38 promoter ( Figure  1 ). CAT expression (Figure 2 ) was substantial in all infected tumor cell types, despite important variations according to the cell type. In contrast, little if any transgene expression was detected in similarly infected normal cells. Among the different tumor cells, the breast adenocarcinoma cell line MCF-7 produced the lowest amount of CAT. Normal rat astrocytes and human fibroblasts were the only normal cells found to express the transgene to significant levels. This result confirms the oncopreferential character of rMVMp-mediated transduction in a new set of biologically relevant in vitro cell systems.
Of the various normal cell types tested in this study, NRN are the only resting ones. The absence of rMVMpmediated transgene expression in these cells is therefore not surprising, on account of the well-known S-phase dependence of the parvoviral life cycle. [26] [27] [28] [29] In the other, proliferating normal cells, the low level of transgene expression clearly indicates that rMVMp selectivity also depends on other cell properties, such as the differentiation state of the host cells (and especially, on whether they have undergone neoplastic transformation). This is precisely what makes such vectors interesting for tumor cell-targeted gene therapy. The most commonly used vec- 30, 31 reported that adenoviral vectors can substantially transduce both cell types.
Although our rMVMp vectors did transfer the transgene preferentially into neoplastic cells, it is noteworthy that some infected normal cells (fibroblasts and astrocytes) displayed low-level transgene expression. Fibroblasts might constitute a particularly favorable target for a vector constructed from the genome of a fibrotropic strain (p) of MVM. 28 On the other hand, parvoviruses are known to replicate preferentially in embryonic or fetal tissues of various animals and in several cycling, poorly differentiated neonate tissues. 32, 33 This might also explain the behavior of rMVMp in NHF, since these cells were derived from a primary cell culture of neonatal prepuce skin. Likewise, NRA were isolated from the brain of a rat embryo. 31 To evaluate the transduction efficiency of MVMpbased vectors at the cellular level, we next infected the different cell types at different multiplicities of infection (MOI) with a recombinant construct expressing the green fluorescent protein (GFP) gene. The proportion of cells expressing GFP was then quantitatively determined by flow cytometry 2 days after infection. Figure 3 shows a representative example of such a FACS analysis in the case of NHF and NB324K cells, while Figure 4 summarizes the results obtained for the different cell types tested. These data roughly confirm the results obtained by CAT ELISA for overall transgene expression ( Figure 2 ). As expected, the percentage of cells expressing the transgene increased with the MOI and varied according to the cell type and to whether the cells were transformed or not. The proportion of normal cells expressing the transgene remained low even after infection at MOI 30 (median: 2.4%, range 0-2.8%), while the proportion of tumor cells expressing the gene at this MOI was significantly higher (median: 42.3, range 11.2-65.8%, Mann-Whitney P Ͻ 0.01).
Interestingly, the FACS data ( Figure 3 ) also revealed a quite similar fluorescence intensity for normal and transformed GFP-positive cells. This means that the major difference between the neoplastic and normal cells resides in the percentage of cells expressing the transgene. Thus, our data indicate that the low transgene expression previously detected in normal cells at the level of the whole cell population (by CAT assay or CAT ELISA) is not due to a low level of gene expression produced by the majority of the cells but rather to a small fraction of cells able to express the transgene efficiently. This observation suggests that the parvoviral oncoselectivity would act rather as an on/off-like system, most normal cells being in the 'off' state and some in the 'on'. The identity, differentiation stage and properties of that small cell population found in some primary cultures of normal cells are still to be characterized. Are they cells already one step further toward transformation (as a result of their in vitro propagation, although normal cells used in this study are early passages of primary cell cultures) or are they close to embryonic cells? These questions and still others will Gene Therapy 
Figure 3 Cytofluorimetric analysis of GFP gene expression in normal versus transformed fibroblasts. 10 4 NHF (upper panels) or NB324K cells (lower panels) were seeded into individual wells of a 24-well microtiter plate. After 24 h, the cells were infected in duplicate overnight either with no virus (left) or with MVM/P38-GFP at MOI 30 (right). The next day, fresh medium was added to the cells which were then grown for 24 h and finally harvested by trypsinization. The cells were fixed in 200-

Figure 4 Cytofluorimetric analysis of GFP gene expression in normal versus tumor cells. The different cells (10 4 to 5 × 10 4 cells per well of a 24-well microtiter plate) were infected either with no virus or with MVM/P38-GFP at MOI 3 or 30. Forty-eight hours after infection, the cells were harvested and GFP expression was measured as described in Figure 3. Abscissa: cell types (a, fibroblasts; b, melanocytes; c, rat neural; d, breast cells); ordinate: transduction efficiency (percent ratio of GFPpositive cells to total cells in the gated region).
have to be answered in order to understand the oncoselectivity of MVMp better.
Our FACS data show that in most of the tumor cell populations infected at MOI 30, the transgene was transferred to one-to two-thirds of the cells (median: 42.3%). This indicates that a relatively high MOI is required for substantially transducing tumor cells by means of rMVMp. The relatively low transduction efficiency of these vectors could result, at least partially, from the dependence of autonomous parvovirus DNA replication and gene expression to the S-phase. Since proliferating tumor cells were not synchronized in our study, only the fraction of the cell population entering in the S-phase at or relatively early after the period of infection can be detected and considered as successfully transduced at the time of the analysis. On the other hand, it is worth mentioning that we observed a significant, dose-dependent cytotoxic effect of rMVMp in infected tumor cells, varying in intensity according to the cell type (data not shown). This effect hindered the precise analysis of rMVMp transduction efficiency, particularly at high MOI. We were thus unable to estimate the MOI required for 100% transduction in the different target cells. Preliminary immunocytochemical analyses of cell cultures infected at high MOI (100-300) indicate that most infected tumor cells are killed under these conditions and that almost all surviving cells express the gene (data not shown). Since cell death is presumably due at least in part to synthesis of cytotoxic NS proteins, it is likely that a fraction of them express the transgene before dying. This suggests that the transduction efficiency may be underestimated in our experiments.
A preliminary analysis suggested the possibility of using MVMp transcription-regulating elements to drive expression of the HSV-TK gene in transformed cells. 34 In order to further evaluate this approach, we constructed a new recombinant of MVMp expressing the HSV-TK gene. Using high-titer rMVMp stocks, we either mock-infected the different cell types or infected them with MVM/P38-TK at MOI 30 (chosen for the good transduction efficiency measured by FACS for all tumor cells, see Figure 4) . Twenty-four hours later we added or did not add a subtoxic dose of GCV (10 g/ml) and we estimated cell survival 4 days after infection by means of the MTT assay. At this MOI and with the help of the possible bystander effect, we believed it should be possible to kill the majority of cells in the different tumor cell populations.
The results presented in Figure 5 show that GCV treatment had no effect on non-infected cells. In the absence of GCV, infection with MVM/P38-TK had no significant effect on the survival of normal cells, except for NRA cells whose survival was reduced by 28%. This contrasts with the situation of tumor cells: in the absence of GCV, survival of most neoplastic cell types was reduced after infection. This GCV-independent cytotoxicity varied considerably according to the tumor cell type, killing 65% of the NB324K cells and 55% of the IGR3 cells, 27% of the MCF7 cells, and 33% of the MDA-MB-231 cells. In contrast, the melanoma cell line RPMI was almost totally resistant to this parvoviral cytopathic effect (MannWhitney P = 0.5127), despite the 32% transduction efficiency observed with rMVMp at MOI 30 in this cell line. When the cells were infected with MVM/P38-TK and subsequently treated with GCV, the survival of nor- 
cells (data not shown). Cell survival (ordinate), expressed as a percentage of the number of control cells (mock-infected cells without GCV), was measured 4 days after infection by means of the MTT assay (Sigma). The height of each column represents the mean of the three values obtained and the bar above it represents the s.d. Normal/transformed cell types: fibroblasts (a); melanocytes (b); rat neural (c); and breast cells (d). *Means that the difference between mock-and rMVMp-infected cells was significant (MannWhitney).
mal fibroblasts and NHMEC was unaffected. A weak cytotoxic effect was observed in NCG cells (16% mortality). Mortality of NRA cells did not differ significantly from that observed in the absence of GCV (around 30%), suggesting that infection and not GCV was the cause of this mortality. Survival of transformed fibroblasts, both melanoma cell lines, and glioma C6 cells, on the other hand, was substantially reduced upon addition of GCV to the infected cell population (mortality ranging from about 80% in both melanoma cell populations to 95% in the NB324K cell population). Surprisingly, not all neoplastic cells were thus affected, since the mammary tumor cell lines MCF-7 and MDA-MB-231 displayed, respectively, only 24 and 42% mortality. In these latter cells, the effect of GCV on rMVMp-infected cells was not significant. It should be noted that rMVMP-mediated transduction of the GFP gene into these cell lines was efficient at MOI 30 (Figure 4 ), since 11% of the MCF-7 cells and 41% of the MDA-MB-231 cells were found to express the transduced gene. Interestingly, connexins are reported to be transcriptionally down-regulated in a variety of human breast cancer cell lines, including MCF-7 and MDA-MB-231 lines. 35, 36 These proteins constitute specialized structures called 'gap junctions' between the plasma membranes of adjacent cells 37 and play a critical role in the bystander effect in vitro. [38] [39] [40] Thus, the absence of GCV-mediated cytotoxicity in both breast tumor cell lines may reflect the absence of significant bystander effect in these cells. To test this hypothesis, we performed experiments in which stably transfected cells constitutively expressing the HSV-TK gene were mixed, in various proportions, with the corresponding HSV-TK-negative parental cells. Four days after addition of 10 g/ml GCV, survival rates near 100% were observed in cultures containing up to 90% HSV-TK-positive mammary tumor cells (of either line) and 10% of the corresponding parental cells. In contrast, survival of NB324K cells dropped to 10% when only 25% of the cell population expressed HSV-TK (data not shown). This observation suggests that the breast cancer cells tested here are resistant to GCVmediated cytotoxicity because (1) at MOI 30, the gene is transduced into only a fraction of cells in the culture and (2) this cell type is not susceptible to the bystander effect.
Our previous data on the selectivity of rMVMpmediated transduction 23 and those presented here indicate a low but significant level of transgene expression in several rMVMp-infected normal cells, particularly normal human fibroblasts and NRA. Whether this could be deleterious to normal cells when the transgene codes for a cytotoxic protein remains to be addressed. Here, we show that with rMVMp we can preferentially target cytotoxicity to tumor cells, whilst affecting normal proliferating cells only marginally if at all. The vector's cytocidal action is due to two distinct effects: (1) an endogenous, GCV-independent effect of the vector itself, due to expression of the viral NS genes; and (2) an exogenous, GCV-dependent cytotoxicity due to expression of the HSV-TK gene. The NS-mediated cytotoxicity varies according to the susceptibility of the target cells tested, several cell types even being apparently resistant to this effect. On the other hand, only rMVMpinfected cells can be subject to the cytotoxic action of NS. Hence, the achievement of massive cell killing by means of the endogenous rMVMp deleterious effect should imply the use of MOIs that allow around 100% of gene transduction to be reached, a condition that is practically impossible to reach in vivo. Thus, the efficient destruction of tumor cells clearly requires the cotransfer of exogenous transgenes capable of directly or indirectly inducing the killing of neighboring, nontransduced cells, such as immuno-stimulating or suicide genes. We demonstrate that, indeed, the transfer of the HSV-TK gene in the presence of GCV allows the killing of the majority of the cell population of most tumor cell types to be achieved via the so-called bystander effect. However, the extent of this bystander killing can vary considerably from one cell type to another, in particular depending on the importance of the intercellular network of gap junctions.
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In summary, we contribute further in vitro evidence, based on several biologically relevant cell models representing different tissue types, that rMVMp vectors can preferentially target transgene expression into cancer cells. We have measured the transduction efficiency achieved with rMVMp and show that after infection at MOI 30, a substantial proportion of cells in most tumor cell populations tested express the foreign gene (roughly one-to two-thirds in most cases). To our knowledge, this is the first quantitative evaluation of the gene transduction efficiency of MVMp-derived vectors. Interestingly, this analysis allowed us to show that the low transgene expression previously found in normal cells at the level of the whole cell population is due to efficient expression of the transgene by a small cell population and not to low expression by the majority of the cells. Lastly, we show that a rMVMp carrying the suicide gene HSV-TK can achieve tumor cell-specific killing in vitro in the presence of GCV. However, GCV-mediated cytotoxicity was not efficient in breast tumor cells, presumably because these cells are not susceptible to the bystander effect.
Taken together, our results suggest that rMVMp vectors could be used as selective vehicles for anticancer gene therapy, and particularly for the delivery of cytotoxic effector genes into tumor cells in vivo. Currently, rMVMp vectors carrying various reporter or effector genes are being evaluated in different in vivo tumor models. Also, we are developing a second-generation vector system specifically designed to impede generation of RCPV via homologous recombination (paper in preparation). Finally, different strategies are being developed to achieve a further substantial increase in the yield of rMVMp production. Notably, we are working on generating a packaging cell line.
